Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs offers a diverse range of top-notch anti-GPC3 recombinant antibodies, meticulously engineered to deliver superior performance. Our cutting-edge platform ensures exceptional specificity, stability, and efficacy, making these antibodies invaluable assets for researchers and developers in the field of targeted cancer therapy.
Glypican-3 (GPC3) is a protein primarily expressed during embryonic development and in hepatocellular carcinoma (HCC) tumor cells. Its unique expression pattern, absent in most normal adult tissues and liver diseases like fatty liver, cirrhosis, hepatitis, or liver damage, makes GPC3 an ideal target for both diagnosing and treating HCC. This specificity allows for the development of diagnostic tools and therapeutic strategies that selectively target HCC cells, minimizing harm to healthy tissues.
Glypican-3; Glypican 3; DGSX; GTR2-2; MXR7; OCI-5; SDYS; SGB; SGBS; SGBS1.
Cell surface heparan sulfate proteoglycans are composed of a membrane-associated protein core substituted with a variable number of heparan sulfate chains. Members of the glypican-related integral membrane proteoglycan family (GRIPS) contain a core protein anchored to the cytoplasmic membrane via a glycosyl phosphatidylinositol linkage. These proteins may play a role in the control of cell division and growth regulation. The protein encoded by this gene can bind to and inhibit the dipeptidyl peptidase activity of CD26, and it can induce apoptosis in certain cell types. Deletion mutations in this gene are associated with Simpson-Golabi-Behmel syndrome, also known as Simpson dysmorphia syndrome. Alternative splicing results in multiple transcript variants.
Cancer-related genes, Disease related genes, Human disease related genes
Intracellular, Membrane (different isoforms)
Cell type enhanced (Fibroblasts, Syncytiotrophoblasts, Muller glia cells, Cytotrophoblasts, Extravillous trophoblasts)
Immune cell enhanced (naive CD4 T-cell, naive CD8 T-cell)
Group enriched (HAP1, Hep G2)
Heterodimer; disulfide-linked (PubMed:14610063). Cleavage by a furin-like convertase results in production of alpha and beta chains which form a disulfide-linked heterodimer (PubMed:14610063). Interacts with DPP4 (PubMed:17549790). Interacts with FGF2 (By similarity). Interacts with WNT5A (PubMed:14610063). Also interacts with WNT3A and WNT7B (PubMed:16227623). Interacts with hedgehog protein SHH; the heparan sulfate chains are not required for the interaction (By similarity). Also interacts with hedgehog protein IHH (By similarity). Interacts with CD81 (By similarity). Interacts with Wnt receptors FZD4, FZD7 and FZD8; the heparan sulfate chains are required for the interaction (PubMed:24496449).
Protease inhibitor
Creative Biolabs provides a collection of recombinant anti-GPC3 antibodies that have been rigorously developed to display high specificity and affinity. These antibodies are available in a variety of forms and are designed for a wide range of studies and therapeutic applications, spanning basic research to therapeutic development. Based on our robust platform, we deliver cutting-edge tools to advance the research of immunology, cancer biology, and related topics, as well as facilitate therapeutics development.
Table 1. Featured anti-GPC3 recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
FAMAB-0560WJ | Human Anti-GPC3 Recombinant Antibody (clone hYP9.1) | Human | Human IgG1, κ | ELISA, WB |
HPAB-0561-CN-S(P) | Mouse Anti-GPC3 Recombinant Antibody (clone GC33); scFv Fragment | Human | Mouse scFv | ELISA |
AFC-TAB-H14 | Afuco™ Anti-GPC3 ADCC Recombinant Antibody (Codrituzumab), ADCC Enhanced | Human | Human, ADCC-enhanced antibody | FuncS, IF, Neut, ELISA, FC, IP |
HPAB-0563-CN | Human Anti-GPC3 Recombinant Antibody (clone hGC33) | Human | Humanized IgG1, κ | ELISA |
TAB-157CT | Human Anti-GPC3 Recombinant Antibody (TAB-157CT) | Human, Cynomolgus monkey, Rat, Mouse | Human, Chimeric (mouse/human) IgG1 | ELISA, FC, IHC, WB |
HPAB-0561-CN | Mouse Anti-GPC3 Recombinant Antibody (clone GC33) | Human | Mouse IgG | ELISA |
Creative Biolabs provides a complete spectrum of anti-GPC3 recombinant antibodies that have undergone rigorous quality testing. Our cutting-edge facilities and expert scientists precisely develop each antibody to target GPC3 with pinpoint accuracy. Through rigorous testing and validation, we ensure that these antibodies exhibit superior specificity, strong binding affinity, and other optical properties in a wide range of research applications.
Fig.1 WB analysis of anti-GPC3 antibody
(Cat# HPAB-0561-CN, Creative Biolabs).
Fig.2 ELISA analysis of anti-GPC3 antibody
(Cat# HPAB-0561-CN, Creative Biolabs).
Fig.3 WB analysis of anti-GPC3 antibody
(Cat# ZG-0690J, Creative Biolabs).
Fig.4 IF analysis of anti-GPC3 antibody
(Cat# ZG-0690J, Creative Biolabs).
Fig.5 WB analysis of anti-GPC3 antibody
(Cat# TAB-263CQ, Creative Biolabs).
Fig.6 ELISA analysis of anti-GPC3 antibody
(Cat# TAB-263CQ, Creative Biolabs).
Creative Biolabs provides a consistent supply of superior anti-GPC3 antibodies that are produced using cutting-edge genetic technologies.
Featured Anti-GPC3 Recombinant Antibody Production Platforms
Fig.7 Milligram-scale anti-GPC3 recombinant antibody production.
Fig.8 Gram-scale anti-GPC3 recombinant antibody production.
Creative Biolabs provides a wide range of high-quality anti-GPC3 recombinant antibodies with diverse formats to meet global researchers’ various demands.
Fig.9 Full-length anti-GPC3 recombinant antibody production and modalities.
Table 2. Public drug targeting GPC3.
Highest Phase | Mechanism of Action | Product Category | Condition | Organization |
National Cancer Center of Japan (Originator) | Phase II |
Cancer Immunotherapy Cancer Vaccines Oligopeptides, less than 10 AA Peptide Vaccines |
Cancer, liver (hepatocellular carcinoma) | |
National Cancer Center of Japan (Originator) | Phase II |
Cancer Immunotherapy Cancer Vaccines Oligopeptides, less than 10 AA Peptide Vaccines |
Cancer, liver (hepatocellular carcinoma) | |
Creagene (JW Creagene) JW Creagene (Originator) |
Phase II |
Cancer Immunotherapy Cancer Vaccines Dendritic Cell Vaccines |
Cancer, liver | |
Chugai Pharmaceutical (Originator) Roche (Originator) |
Phase II |
Cancer Immunotherapy Humanized Monoclonal Antibodies |
Cancer, liver Cancer, liver (hepatocellular carcinoma) |
|
AbelZeta AstraZeneca (Originator) |
Phase I/II |
Cancer Immunotherapy Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) |
Cancer, liver (hepatocellular carcinoma) | |
Sanofi (Originator) | Phase I/II |
Cancer Immunotherapy Single-Domain Antibodies |
Cancer, liver (hepatocellular carcinoma) Cancer, lung (non-small cell) (NSCLC) Cancer, solid tumor |
|
KeyMed Biosciences (Originator) | Phase I/II |
Bispecific Antibodies Cancer Immunotherapy |
Cancer, solid tumor | |
OriCell Therapeutics (Originator) | Phase I/II |
Cancer Immunotherapy Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR) |
Cancer, liver (hepatocellular carcinoma) | |
Eureka Therapeutics (Originator) | Phase I/II |
Adoptive Cell Therapy Cancer Immunotherapy |
Cancer, liver (hepatocellular carcinoma) | |
Cogent Biosciences (Originator) SOTIO Biotech SOTIO (SOTIO Biotech) Unum Therapeutics (Cogent Biosciences) |
Phase I/II |
Cancer Immunotherapy Chimeric Antigen Receptor-Modified T Cells (CAR T Cells) (Second-Generation CAR) |
Cancer, liver (hepatocellular carcinoma) Cancer, lung (non-small cell) (NSCLC) (squamous cell carcinoma) Cancer, solid tumor Carcinoma, Merkel cell Liposarcoma, myxoid-round cell |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
For more information or to inquire about our anti-GPC3 recombinant antibody products, please contact us at any time.